Search is Powered by Google
Allergy News

FDA Approves Labeling Change For Non-Drowsy CLARITIN(R)

Main Category: Allergy
Also Included In: Regulatory Affairs / Drug Approvals;  Pharma Industry / Biotech Industry
Article Date: 23 Jan 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Schering-Plough (NYSE: SGP) announced that the U.S. Food and Drug Administration has approved additional labeling for CLARITIN(R) (loratadine), which clearly tells consumers that the non-drowsy over-the-counter medication relieves allergy symptoms caused by both indoor (also called perennial or year-round) and outdoor (also called seasonal) allergies.

"Schering-Plough is pleased that the FDA has approved the change to the CLARITIN label to help us to communicate to consumers that CLARITIN works hard to relieve both indoor and outdoor allergies," said John E. O'Mullane, BSc, PhD, Group Vice-President, Research and Development, Schering-Plough Consumer Health Care.

Common indoor allergens include mold, dust mites, and pet dander, while common outdoor allergens include grass, tree, and ragweed pollen. Though they stem from different sources, indoor and outdoor allergies have the same pathophysiology, meaning they affect the body in the same way. Symptoms of both types of allergies include runny nose; sneezing; itchy, watery eyes; and itching of the nose or throat.

"People often associate allergies with outdoor triggers like pollen and grass, but many people's allergies are actually caused by things found in their home, office, or school," said Marjorie Slankard, M.D., allergist and clinical professor of medicine at the Columbia University College of Physicians and Surgeons. "When choosing an allergy medication, it's important to recognize that not all treatments are the same. Many patients and providers prefer a non-drowsy antihistamine, such as CLARITIN, because of its proven record in relieving symptoms of indoor and outdoor allergies." CLARITIN is the only brand proven to keep allergy sufferers as alert and focused as someone without allergies.* Allergy sufferers who are unsure about which treatment option is right for them should talk to their doctors.

CLARITIN is approved as effective against indoor (perennial) allergies in 110 countries worldwide.

Only brand clinically tested.

About CLARITIN

All CLARITIN brand products are available without a prescription, including: CLARITIN Tablets, a once-daily full prescription strength, non- drowsy formulation; CLARITIN RediTabs(R) Tablets, a novel once-daily formulation in a quickly dissolving tablet for ages 6 and older; CLARITIN-D(R) 24-hour and 12-hour Extended Release Tablets, with the decongestant pseudoephedrine now located behind the counter; CHILDREN'S CLARITIN(R) Syrup, a liquid formulation for children ages 2 and older in grape and fruit flavors; CHILDREN'S CLARITIN(R) Grape Chewables, a chewable tablet for children ages 2 and older; and CLARITIN Hives Relief(TM) tablets.

CLARITIN is the No. 1 physician-recommended and pediatrician-recommended over-the-counter antihistamine brand for allergic rhinitis. The CLARITIN Rx- to-OTC switch in 2002 was the largest switch ever-and the first and only for a non-sedating antihistamine. For more information on allergies and treatment, visit http://www.CLARITIN.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

Schering-Plough
http://www.schering-plough.com






Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
FDA To Recommend That Doctors Conduct Genetic Screening Before Prescribing Antiretroviral Abacavir To Reduce Allergic Reactions
25 Jul 2008
FDA on Thursday is expected to issue an advisory that urges physicians to conduct genetic testing before prescribing GlaxoSmithKline's antiretroviral drug abacavir to reduce allergic reactions in people taking the drug, the...


Keeping a Personal Medical Record image Keeping a Personal Medical Record

Medical information is usually scattered in many different places. To receive the best possible health care, people are encouraged to gather information in one place and create a personal medical record...

Improving Health Care image Improving Health Care

Improvements are necessary to make sure Americans get the best quality health care and that money for this care is being spent as effectively as possible. Listen as experts -- both in government and in the private sector -- describe some of the steps taken to improve the health care system...

View more videos...